Table 1 Baseline characteristics
Characteristics | Study arms | |
|---|---|---|
Arm 1: Immediate (n = 24) | Arm2: Deferred (n = 19) | |
Gender [M : F], n (%) | 10: 14 (42 : 58) | 7: 12 (37 : 63) |
Median age, years (IQR) | 5.2 (2.4 – 8.0) | 4.4 (2.7 – 5.8) |
Age group, n (%) | ||
   ○ 1 – 4 yrs | 12 (50) | 10 (53) |
   ○ 5 – 12 yrs | 12 (50) | 9 (47) |
Median weight for age z-scores (WAZ) (IQR) | -1.0 (-1.5 to 0.4) | -0.1 (-1.5 to 0.3) |
Median height for age z-scores (WAZ) (IQR) | -1.7 (-2.0 to -0.9) | -0.8 (-1.7 to 0.1) |
HIV transmission, n (%) | ||
   ○ Blood product or transfusion recipient | 2 (8) | 0 |
   ○ Mother to child transmission | 21 (88) | 19 (100) |
   ○ Unclear | 1 (4)* | 0 |
Exposed to AZT as prophylaxis against vertical HIV transmission, n (%)** | 5/13 (39) | 4/11 (37) |
CDC categories, n (%) | ||
   ○ A | 20 (83) | 16 (84) |
   ○ B | 4 (17) | 3 (16) |
Median percent CD4+ count, % (IQR) | 19 (16 – 22) | 20 (17 – 22) |
Median CD4+ count, cells/mm3 (IQR) | 649 (509 – 834) | 615 (544 – 818) |
Median plasma viral load, log10 copies/ml (IQR) | 4.8 (4.3 – 5.3) | 4.8 (4.1 – 5.1) |
Median hemoglobin, g/dl (IQR) | 10.8 (10.2 – 11.7) | 11.2 (10.6 – 11.8) |
Median alanine transferase, IU/L (IQR) | 20 (11 – 30) | 17 (15 – 23) |
Median glucose (mg/dL) at week 48 | 83 (74 – 90) | 81.5 (70.5 – 88) |
Median cholesterol (mg/dL) at week 48 | 173 (153 – 195) | 165 (150 – 186) |
Median triglyceride (mg/dL) at week 48 | 69 (54 – 88) | 98 (70 – 148) |